1. Pink Sheet

AstraZeneca Playing Leapfrog In Immunotherapy: How It Plans To Lead From Behind

 
• By Mary Jo Laffler

AstraZeneca has not been at the front of the PD-1/L1 immune checkpoint inhibitor race, but execs explain how the company is making strategic choices in immuno-oncology to make it first to the finish line in unique areas.

In the field of cancer immunotherapy, the name of the game for AstraZeneca PLC is leapfrog.

The ability to unlock cancer cells’ innate defensive mechanisms against the immune system, boost and refocus an immune response –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D